Valuation Remus Pharmaceuticals Limited

Stocks

Market Closed - NSE India S.E. 07:05:09 2026-09-28 EDT			5-day change	1st Jan Change
919.50 ^INR	-2.80%		-6.08%	+30.95%

05-30	295,000 Equity Shares of Remus Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 31-MAY-2026.	CI
05-21	Remus Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI

Data adjusted to current consolidation scope

Fiscal Period: March	2024	2025	2026
Market Cap ¹	10,163	13,192	7,320
Change	-	29.81%	-44.51%
Enterprise Value (EV) ¹	9,985	13,149	7,042
Change	-	31.69%	-46.45%
P/E	45.4x	45.4x	20x
PBR	11.7x	5.1x	2.11x
PEG	0.6x	1.5x	0.7x
Capitalization / Revenue	4.77x	2.13x	0.86x
EV / Revenue	4.69x	2.12x	0.82x
EV / EBITDA	34.6x	28.7x	12.6x
EV / EBIT	35.7x	29.5x	13.1x
EV / FCF	-47.5x	-127x	259x
FCF Yield	-2.1%	-0.79%	0.39%
Dividend per Share ²	0.75	0.75	1
Rate of return	0.09%	0.07%	0.16%
EPS ²	19	24.67	31.39
Distribution rate	3.95%	3.04%	3.19%
Net sales ¹	2,129	6,204	8,536
EBITDA ¹	288.4	457.9	560.1
EBIT ¹	279.7	446	539.3
Net income ¹	215.4	290.7	369.9
Net Debt ¹	-178	-42.9	-278.4
Reference price ²	862.42	1,119.48	627.90
Nbr of stocks (in thousands)	11,784	11,784	11,658
Announcement Date	8/29/24	9/2/25	9/8/26

¹INR in Million²INR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
REMUS PHARMACEUTICALS LIMITED	-	-	-	-	116M
ELI LILLY AND COMPANY	33.65x	12.19x	24.78x	0.59%	1,055B
JOHNSON & JOHNSON	30.17x	6.71x	18.78x	1.98%	654B
ABBVIE INC.	33.43x	7.82x	16.17x	2.59%	467B
ROCHE HOLDING AG	19.59x	4.78x	11.84x	2.78%	348B
NOVARTIS AG	20.4x	5.31x	13.17x	3.01%	275B
ASTRAZENECA PLC	21.19x	4.39x	12.5x	2.01%	258B
AMGEN INC.	26.19x	6.82x	12.15x	2.43%	224B
GILEAD SCIENCES, INC.	-45.65x	6.64x	25.94x	2.18%	187B
NOVO NORDISK A/S	11.33x	4.13x	8.58x	4.44%	171B
Average	16.70x	6.53x	15.99x	2.45%	363.85B
Weighted average by Cap.	24.18x	7.87x	18.13x	1.96%